Impact of molecular genotyping on the diagnosis and treatment of human chorionic gonadotropin-producing tumors Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • OBJECTIVES: To assess the use of molecular genotyping to accurately diagnose and treat human chorionic gonadotropin (hCG)-producing tumors and to evaluate the discriminating capacity of molecular testing on prognosis and overall survival. METHODS: We conducted a retrospective descriptive study of patients registered with the French Reference Center for Trophoblastic Disease between 1999 and 2021. We included all patients with hCG-producing tumors for whom results of molecular genotyping were available. RESULTS: Fifty-five patients with molecular genotyping were included: 81.2 % (n = 45) had tumors of gestational origin, 12.7 % (n = 7) of non-gestational origin and 5.5 % (n = 3) of undetermined origin. The results of molecular genotyping influenced the treatment decisions for 17 % of patients in this cohort. Overall survival was 93.3 % for patients with gestational tumors (after a median follow-up of 74 months) compared to 71.4 % for patients with non-gestational tumors (after a median follow-up of 23 months). CONCLUSION: In atypical presentations of hCG-producing tumors, molecular genotyping is a valuable tool to guide diagnosis and tailor treatment recommendations.


  • Peyle, M
  • Massoud, M
  • Patrier, S
  • Gaillot-Durand, L
  • Side, G
  • Devouassoux-Shisheboran, M
  • Massardier, J
  • Descargues, P
  • Msika, A
  • Hajri, T
  • Rousset, P
  • Haesebaert, J
  • Lotz, JP
  • Jamelot, M
  • You, B
  • Golfier, F
  • Eiriksson, Lua
  • Allias, F
  • Bolze, PA

publication date

  • January 2024